Compare OBT & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | OBT | LXEO |
|---|---|---|
| Founded | 1892 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 457.5M | 387.1M |
| IPO Year | 2021 | 2023 |
| Metric | OBT | LXEO |
|---|---|---|
| Price | $37.45 | $4.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $36.00 | $18.44 |
| AVG Volume (30 Days) | 94.8K | ★ 928.6K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.12% | N/A |
| EPS Growth | 34.82 | ★ 39.81 |
| EPS | ★ 0.85 | N/A |
| Revenue | N/A | ★ $654,000.00 |
| Revenue This Year | $14.27 | N/A |
| Revenue Next Year | $7.99 | N/A |
| P/E Ratio | $44.29 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.25 | $3.60 |
| 52 Week High | $40.10 | $10.99 |
| Indicator | OBT | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 65.16 | 46.90 |
| Support Level | $32.82 | $4.44 |
| Resistance Level | $40.10 | $5.34 |
| Average True Range (ATR) | 1.40 | 0.34 |
| MACD | 0.10 | 0.03 |
| Stochastic Oscillator | 49.17 | 42.48 |
Orange County Bancorp Inc is a community bank holding company providing commercial and consumer banking services to individuals, small businesses, and local governments. It operates through two segments: Banking and Wealth Management. The Banking segment, the primary revenue driver, offers loans such as commercial real estate, construction, commercial & industrial, multifamily, and residential mortgages, along with services like cash management, escrow, deposits, ATMs, and digital banking. The Wealth Management segment provides investment management, trust services (trustee, administrator, custodian), and financial planning and advisory services to individuals and institutions.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.